Longer-last­ing Botox com­peti­tor nabs FDA ap­proval — can it com­pete with Ab­b­Vie's $2B cash cow?

Re­vance Ther­a­peu­tics an­nounced Thurs­day that its first FDA ap­proval has fi­nal­ly ar­rived for its Botox com­peti­tor, known as Daxxi­fy, af­ter ini­tial­ly sub­mit­ting its orig­i­nal BLA way back in Jan­u­ary 2020.

The bot­u­linum tox­in prod­ucts will com­pete to tem­porar­i­ly im­prove mod­er­ate to se­vere frown lines, and for what Re­vance es­ti­mates is a $3.2 bil­lion and grow­ing mar­ket.

Re­vance is look­ing to cor­ner a slice of that mar­ket with its longer-last­ing, po­ten­tial­ly twice-year­ly in­jec­tion, where­as those us­ing Botox may have to re­turn for more in­jec­tions every three to four months. Wall Street biotech an­a­lysts pre­vi­ous­ly in­di­cat­ed that this dif­fer­ence may be key for Re­vance in do­ing bet­ter than oth­er pre­vi­ous­ly launched Botox knock-offs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER